Tests ADN : en faillite, 23andMe vend sa banque de données à un groupe pharmaceutique | Les Echos


Bankrupt genetic testing company 23andMe sold its DNA database containing information from 15 million people to Regeneron Pharmaceuticals for $256 million.
AI Summary available — skim the key points instantly. Show AI Generated Summary
Show AI Generated Summary

Voir ses données personnelles (adresse, numéro de téléphone, etc.) passer de main en main est déjà inquiétant, alors que dire lorsqu'il s'agit de son profil ADN ? Lundi, la société de tests génétiques en faillite 23andMe a accepté de vendre sa banque de données, qui contient des échantillons d'ADN d'environ 15 millions de personnes, au développeur de médicaments Regeneron Pharmaceuticals, pour 256 millions de dollars.

Was this article displayed correctly? Not happy with what you see?

Tabs Reminder: Tabs piling up in your browser? Set a reminder for them, close them and get notified at the right time.

Try our Chrome extension today!


Share this article with your
friends and colleagues.
Earn points from views and
referrals who sign up.
Learn more

Facebook

Save articles to reading lists
and access them on any device


Share this article with your
friends and colleagues.
Earn points from views and
referrals who sign up.
Learn more

Facebook

Save articles to reading lists
and access them on any device